Insights into atherosclerosis from invasive and non-invasive imaging studies: Should we treat subclinical atherosclerosis?

Atherosclerosis

Volumn 205, Issue 2, 2009, Pages 349-356

  Santos, Raul D ^a   Nasir, Khurram ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Carotid intima media thickness; Coronary artery calcification; Intravascular ultrasound; Low density lipoprotein cholesterol; Magnetic resonance imaging; Statins; Subclinical atherosclerosis

Indexed keywords

ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTERIAL WALL THICKNESS; ARTERY CALCIFICATION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B SCAN; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK POPULATION; HYPERCHOLESTEROLEMIA; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ADULT; AGED; ATHEROSCLEROSIS; CAROTID ARTERIES; CHOLESTEROL, LDL; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, ANATOMIC; PYRIMIDINES; RISK ASSESSMENT; RISK FACTORS; SULFONAMIDES; TUNICA INTIMA; TUNICA MEDIA;

EID: 67651037100     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.12.017     Document Type: Review

References (53)

1. American Heart Association. Heart Disease and Stroke Statistics-2007 Update (2007), American Heart Association, Dallas, TX
2. Grundy S.M. Age as a risk factor: you are as old as your arteries. Am J Cardiol 83 (1999) 1455-1457
3. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 90 (1994) 2126-2146
4. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
5. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
6. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
7. Zaman A.G., Helft G., Worthley S.G., and Badimon J.J. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149 (2000) 251-266
8. Smith Jr. S.C., Greenland P., and Grundy S.M. Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. Circulation 101 (2000) 111-116
9. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
10. Greenland P., Smith Jr. S.C., and Grundy S.M. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 104 (2001) 1863-1867
11. Pitt B., and Rubenfire M. Risk stratification for the detection of preclinical coronary artery disease. Circulation 99 (1999) 2610-2612
12. Bots M.L., Hoes A.W., Koudstaal P.J., et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96 (1997) 1432-1437
13. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 340 (1999) 14-22
14. Taylor A.J., Feuerstein I., Wong H., Barko W., Brazaitis M., and O'Malley P.G. Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project. Am Heart J 141 (2001) 463-468
15. Kondos G.T., Hoff J.A., Sevrukov A., et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 107 (2003) 2571-2576
16. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., and Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007) 459-467
17. Baldassarre D., Amato M., Pustina L., et al. Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. Atherosclerosis 191 (2007) 403-408
18. Nasir K., Michos E.D., Blumenthal R.S., and Raggi P. Detection of high-risk young adults and women by coronary calcium and NCEP Panel III guidelines. J Am Coll Cardiol 46 (2005) 1931-1936
19. Expert Panel on Detection, Evaluation and, Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 106 (2002) 3143-3421
20. Greenland P., Bonow R.O., Brundage B.H., et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 49 (2007) 378-402
21. Grewal J., Anand S., Islam S., Lonn E., and on behalf of the SHARE and SHARE-AP Investigators. Prevalence and predictors of subclinical atherosclerosis among asymptomatic "low risk" individuals in a multiethnic population. Atherosclerosis 197 (2008) 435-442
22. Raggi P., Shaw L.J., Berman D.S., and Callister T.Q. Prognostic value of coronary arterial calcium screening in subjects with and without diabetes. J Am Coll Cardiol 43 (2004) 1663-1669
23. Grundy S.M., Cleeman J.I., Bairey Merz C.N., et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
24. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
25. Rosenson R.S. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 1 (2001) 411-420
26. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
27. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
28. Mercuri M., Bond M.G., Sirtori C.R., et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 101 (1996) 627-634
29. Blankenhorn D.H., Azen S.P., Kramsch D.M., et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study. Ann Intern Med 119 (1993) 969-976
30. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344 (1994) 633-638
31. Waters D., Higginson L., Gladstone P., et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89 (1994) 959-968
32. Pitt B., Mancini G.B.J., Ellis S.G., Rosman H.S., Park J.-S., McGovern M.E., and for the PLAC I Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 26 (1995) 1133-1139
33. Herd J.A., Ballantyne C.M., Farmer J.A., et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 80 (1997) 278-286
34. Taylor A.J., Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., and Vernalis M.N. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intimal medial thickness. Circulation 106 (2002) 2055-2060
35. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
36. Nissen S.E., Nicholls S.J., Sipahi I., et al. for the ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
37. Sipahi I., Nicholls S.J., Tuzcu E.M., and Nissen S.E. Coronary atherosclerosis can regress with very intensive statin therapy. Cleve Clin J Med 73 (2006) 937-944
38. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J.P., and Stalenhoef A.F.H. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357 (2001) 577-581
39. Crouse III J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 297 (2007) 1344-1353
40. Corti R., Fuster V., Fayad Z.A., et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106 (2002) 2884-2887
41. Underhill H.R., Yuan C., Zhao X.-Q., et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 155 584 (2008) e1-e8
42. Hatsukami T., Zhao X.Q., Kraiss L.W., et al. Assessment of rosuvastatin treatment on carotid atherosclerosis in moderately hypercholesterolemic subjects using high-resolution magnetic resonance imaging. Eur Heart J 26 (2005) 626 [abstr]
43. Raggi P., Davidson M., Callister T.Q., et al. Aggressive versus moderate lipid-lowering therapy in hyper cholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering With EBT Scanning (BELLES). Circulation 112 (2005) 563-571
44. Kastelein J.J.P., Akdim F., Stroes E.S.G., et al. for the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443
45. Callister T.Q., Raggi P., Cooil B., Lippolis N.J., and Russo D.J. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 339 (1998) 1972-1978
46. Raggi P., Callister T.Q., and Shaw L.J. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol 24 (2004) 1272-1277
47. Arad Y., Spadaro L.A., Roth M., Newstein D., and Guerci A.D. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 46 (2005) 166-172
48. Nicholls S.J., Tuzco E.M., Wolski K., et al. Coronary artery calcification and changes in atheroma burden in response to established medical therapies. J Am Coll Cardiol 49 (2007) 263-270
49. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose-positron emission tomography. J Am Coll Cardiol 48 (2006) 1825-1831
50. Greenland P., LaBree L., Azen S.P., Doherty T.M., and Detrano R.C. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 291 (2004) 210-215
51. Hendel RC, Patel MR, Kramer CM, Poon, M. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR. Appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol 2006;48:1475-97.
52. Ford E.S., Giles W.H., and Mokdad A.H. The distribution of 10-year risk for coronary heart disease among US. adults: findings from the National Health and Nutriton Examination Survey III. J Am Coll Cardiol 43 (2004) 1791-1796
53. Naghavi M., Falk E., Hecht H.S., et al. From vulnerable plaque to vulnerable patient. Part III. Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol 98 2A (2006) 2H-15H